CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity

Chimeric antigen receptor (CAR) T cell therapy represents a significant advancement in cancer therapy. Larger studies have shown ∼90% complete remission rates against chemoresistant and/or refractory CD19(+) leukemia or lymphoma. Effective CAR T cell therapy is highly dependent on lymphodepleting pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kueberuwa, Gray, Kalaitsidou, Milena, Cheadle, Eleanor, Hawkins, Robert Edward, Gilham, David Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772011/
https://www.ncbi.nlm.nih.gov/pubmed/29367945
http://dx.doi.org/10.1016/j.omto.2017.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772011/
https://www.ncbi.nlm.nih.gov/pubmed/29367945
http://dx.doi.org/10.1016/j.omto.2017.12.003

Ejemplares similares